STING1 and neoplasm: Due to the antitumoral impacts of cGAMP, various forms of CDN‐centered STING agonists are, as of now, under scrutiny at clinical preliminaries for several tumor types.121 Ritchie et al. recently determined that cGAMP could perform a unique function as an extracellular immunotransmitter, to serve as a solvent that is delivered and emitted by tumor cells.